Andere talen HBM Holdings Limited

Aandelen

2142

KYG4403H1002

Beurs gesloten - Hong Kong S.E. Andere beurzen 10:08:20 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,25 ^HKD	+5,04%		+16,82%	-35,57%

02/04	HBM Holdings wordt weer winstgevend in 2023	MT
28/03	HBM Holdings Limited rapporteert resultaten voor het gehele jaar eindigend op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

HBM Holdings Returns to Profitability in 2023	02/04
Harbour BioMed Reports Full Year 2023 Financial Results	28/03
HBM Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
HBM Holdings Subsidiary Signs Antibody-Drug Conjugate Discovery Collaboration Deal	27/02
HBM Holdings Gets US FDA Clinical Trial Approval for Anti-Tumor Medication	24/01
Harbour BioMed Announces IND Clearance for HBM9027 in the U.S	24/01
HBM to Swing to 2023 Profit	19/01
Harbour BioMed Announces Positive Profit Alert	19/01
HBM Holdings Limited Provides Earnings Guidance for the Year Ended 31 December 2023	19/01
HBM Holdings Limited commences an Equity Buyback Plan for 76,842,891 shares, representing 10% of its issued share capital, under the authorization approved on June 8, 2023.	19/12
Harbour BioMed's Wholly-owned Subsidiary Nona Biosciences Enters into a Global License Agreement with Pfizer for HBM9033, an MSLN-Targeted Antibody-Drug Conjugate	15/12
HBM Holdings Unit Nona Biosciences Signs Licensing Deal with Seagen for Tumor Medication; Shares Fall 5%	15/12
HBM Holdings Limited Announces Results of the Phase Iii Clinical Trial, Which Demonstrated That the Efficacy in the Primary and Secondary Endpoints of Batoclimab	01/12
HBM Holdings Limited Announces Executive Changes	19-10-23
HBM Swings to Profit in H1; Shares Up 6%	29-08-23
HBM Gets US FDA Clearance to Hold Anti-Tumor Drug Trials in US	29-08-23
Harbour BioMed Announces US IND Clearance of Its First ADC Program HBM9033 in Solid Tumors	28-08-23
HBM Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2023	28-08-23
Harbour BioMed Appoints Dr. Albert R. Collinson as Independent Non-Executive Director	08-08-23
Harbour BioMed Appoints Dr. Albert R. Collinson as Independent Non-Executive Director	08-08-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen HBM Holdings Limited

Aandelen

2142

KYG4403H1002

Andere talen

Filters